Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00529568
Registration number
NCT00529568
Ethics application status
Date submitted
12/09/2007
Date registered
14/09/2007
Date last updated
5/11/2013
Titles & IDs
Public title
Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease
Query!
Scientific title
Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2b Plus Ribavirin)
Query!
Secondary ID [1]
0
0
TPL108390
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hepatitis C, Chronic
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - eltrombopag
Treatment: Drugs - placebo
Experimental: eltrombopag - active treatment arm
Placebo Comparator: placebo - placebo control arm
Treatment: Drugs: eltrombopag
double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
Treatment: Drugs: placebo
double-blind matched placebo control daily oral administration
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase
Query!
Assessment method [1]
0
0
Participants with SVR are defined as those with non-detectable Hepatitis C Virus (HCV) ribonucleic acid (RNA) at the end of treatment and all subsequent planned visits up to 24 weeks post-completion of the treatment period of the DB Phase.
Query!
Timepoint [1]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [1]
0
0
Number of Participants Whose Platelet Count Increased From a Baseline Count of <75 Gi/L to a Count Greater Than or Equal to (>=) 100 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase
Query!
Assessment method [1]
0
0
Participants were assessed for a shift from a baseline platelet count of <75 Gi/L to a count >=100 Gi/L during the OL Phase (up to 9 weeks). Local laboratories were used for platelet function tests. Platelet counts were measured by blood draw.
Query!
Timepoint [1]
0
0
From Baseline up to Week 9 in the OL Phase
Query!
Secondary outcome [2]
0
0
Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase
Query!
Assessment method [2]
0
0
In the OL Phase, participants initially received the lowest dose of eltrombopag (25 mg QD) for 2 weeks. If after this time the platelet count was <100 Gi/L, participants underwent sequential dose escalation to the next highest dose (50 mg QD for up to 2 weeks), with further dose escalations to 75 mg QD (up to 2 weeks) and 100 mg QD (up to a maximum of 3 weeks) if platelet counts remained <100 Gi/L. Participants who achieved platelet counts >=100 Gi/L when receiving any of the eltrombopag doses in the OL Phase initiated antiviral therapy in the DB Phase.
Query!
Timepoint [2]
0
0
From Baseline up to Week 9 in the OL Phase
Query!
Secondary outcome [3]
0
0
Median Platelet Count at the Indicated Time Points During the OL Phase
Query!
Assessment method [3]
0
0
Blood taken from peripheral blood vessels was used for the measurement of platelet counts. The Last On Treatment assessment refers to the actual last treatment assessment, not necessarily to the End of Treatment assessment entered by the Investigator.
Query!
Timepoint [3]
0
0
OL Phase: Baseline; Day 1; Weeks 1, 2, 3, 4, 5, 6, 7, 8, and 9; Antiviral Baseline (up to Week 10); End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 62); 12-week FU (up to Week 70); and 24-week FU (up to Week 82)
Query!
Secondary outcome [4]
0
0
Median Platelet Count at the Indicated Time Points During the DB Phase
Query!
Assessment method [4]
0
0
Blood taken from peripheral blood vessels was used for the measurement of platelet counts. The Last On Treatment assessment refers to the actual last treatment assessment, not necessarily to the End of Treatment assessment entered by the Investigator.
Query!
Timepoint [4]
0
0
DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Query!
Secondary outcome [5]
0
0
Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy
Query!
Assessment method [5]
0
0
The minimum platelet count with antiviral therapy was categorized as follows: <25 Gi/L; >=25 to <50 Gi/L; >=50 to <90 Gi/L; >=90 to <150 Gi/L; >=150 Gi/L to <200 Gi/L; >=200 Gi/L to <400 Gi/L; and >=400 Gi/L.
Query!
Timepoint [5]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [6]
0
0
Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase
Query!
Assessment method [6]
0
0
RVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment. eRVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment that persisted through Week 12.
Query!
Timepoint [6]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [7]
0
0
Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase
Query!
Assessment method [7]
0
0
EVR is defined as a clinically significant reduction from Baseline in HCV RNA (>=2 log10 drop or undetectable) after 12 weeks of antiviral treatment. cEVR is defined as undetectable HCV RNA after 12 weeks of antiviral treatment.
Query!
Timepoint [7]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [8]
0
0
Number of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase
Query!
Assessment method [8]
0
0
ETR is defined as the absence of detectable HCV RNA at the end of antiviral treatment. SVR12 is defined as the absence of detectable HCV RNA at the end of antiviral treatment and the 12-week follow-up assessment.
Query!
Timepoint [8]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [9]
0
0
Number of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase
Query!
Assessment method [9]
0
0
Participants were assigned a score equal to the number of times their dose of antiviral therapy (peginterferon or ribavirin) was reduced (0=no dose reductions [DRs]; 1=one DR; 2=two DRs; 3=three DRs; >3=more than three DRs). When possible, every effort was made to maintain the recommended dose of antiviral therapy for the treatment duration in the DB Phase. However, when dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of peginterferon and ribavirin.
Query!
Timepoint [9]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [10]
0
0
Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase
Query!
Assessment method [10]
0
0
Time to first dose reduction was calculated as the time period from the first dose to the first dose reduction.
Query!
Timepoint [10]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [11]
0
0
Number of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase
Query!
Assessment method [11]
0
0
The assigned dose in the DB Phase of peginterferon alfa-2a was 180 micrograms (µg). For peginterferon dose modification, downward adjustments in one-level increments were considered. The lowest dose of peginterferon alfa-2a that was allowed to be administered was 45 µg. When dose adjustment was required for moderate to severe adverse reactions (clinical and/or laboratory), an initial dose reduction to 135 µg was generally adequate. In some cases, a dose reduction to 90 µg or 45 µg was necessary. Dose increases toward the original dose were considered when the adverse reaction was resolved.
Query!
Timepoint [11]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [12]
0
0
Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase
Query!
Assessment method [12]
0
0
The following participants were considered to have discontinued antiviral therapy: participants who were lost to follow-up; participants who withdrew for any reason; participants who died; participants who otherwise did not complete their planned course of antiviral therapy for any reason. The planned duration of antiviral therapy was 48 weeks for participants with Non-Genotype 2/3 and 24 or 48 weeks for participants with Genotype 2/3.
Query!
Timepoint [12]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [13]
0
0
Number of Participants Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3)
Query!
Assessment method [13]
0
0
There are two genetic variants (rs12979860 and rs8099917) mapping near IL28B associated with both interferon-induced SVR and spontaneous HCV clearance. IL28B genotype distribution by response to antiviral therapy (SVR/RVR responders: those who achieved SVR/RVR; SVR/RVR non-responders: those who did not achieve SVR/RVR) was assessed. The effect of genotype was tested by comparing participants that carried 2 copies of the IL28B favorable response allele versus the others (recessive model). Genotypes at rs12979860 were coded as: CC=1, CT or TT=0; rs8099917 was coded as TT=1, GT or GG=0.
Query!
Timepoint [13]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [14]
0
0
Number of Participants With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS)
Query!
Assessment method [14]
0
0
Blood samples for the assessment of clinical chemistry parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of calcium (low=hypocalcemia; high=hypercalcemia), glu. (low=hypoglycemia; high=hyperglycemia), pot. (low=hypokalemia; high=hyperkalemia), and sod. (low=hyponatremia; high=hypernatremia). Per the DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
Query!
Timepoint [14]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [15]
0
0
Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS
Query!
Assessment method [15]
0
0
Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
Query!
Timepoint [15]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [16]
0
0
Number of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication
Query!
Assessment method [16]
0
0
Ophthalmic (pertaining to eye) assessments were performed during the study. A cataract event is defined as an event ascertained to be a cataract (opacity or cloudiness of the lens of the eye, causing impairment of vision) by at least one of the CEC members (comprised of expert ophthalmologists who provided objective medical review of the blinded ophthalmic data). Per the CEC, cataract events were categorized as: (1) Cataract Progression (CP; progression of cataracts present at BL); and (2) Incident Cataract (IC; development of new cataracts). One eye=unilateral; both eyes=bilateral.
Query!
Timepoint [16]
0
0
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Query!
Secondary outcome [17]
0
0
Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase
Query!
Assessment method [17]
0
0
Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal, all ECG parameters within accepted normal ranges. Abnormal, ECG finding(s) outside of normal ranges. CS, ECG with a CS abnormality that meets exclusion criteria. NCS, ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.
Query!
Timepoint [17]
0
0
DB Phase: Antiviral BL (up to Week 10); End of Treatment (up to Week 52); and 24-week FU (up to Week 72)
Query!
Secondary outcome [18]
0
0
Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase
Query!
Assessment method [18]
0
0
Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with a CS and a NCS change from baseline in ECG status, as determined by the Investigator, was reported. CS, ECG with a CS abnormality that meets exclusion criteria. NCS, ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment. "Not applicable" indicates that information was not provided by the investigator on whether the change from baseline ECG was CS or NCS.
Query!
Timepoint [18]
0
0
End of Treatment (up to Week 52); and 24-week FU (up to Week 72)
Query!
Secondary outcome [19]
0
0
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During the DB Phase
Query!
Assessment method [19]
0
0
Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
Query!
Timepoint [19]
0
0
DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Query!
Secondary outcome [20]
0
0
Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase
Query!
Assessment method [20]
0
0
Heart rate was measured in participants at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
Query!
Timepoint [20]
0
0
DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Query!
Secondary outcome [21]
0
0
Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase
Query!
Assessment method [21]
0
0
The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
Query!
Timepoint [21]
0
0
DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Query!
Secondary outcome [22]
0
0
Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase
Query!
Assessment method [22]
0
0
The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
Query!
Timepoint [22]
0
0
DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Query!
Eligibility
Key inclusion criteria
Male and female subjects, >18 years Evidence of chronic hepatitis C virus (HCV) infection
Subjects who are appropriate candidates for peginterferon (pegIFN) and ribavirin antiviral
therapy A platelet count of <75,000/mcL Haemoglobin >11.0g/dL for men or >10.0g/dL for
women Absolute neutrophil count (ANC) >750/mm3 and no history of infections associated with
neutropenia Creatinine clearance >50mL/minute All fertile males and females must use two
forms of effective contraception between them during treatment and during the 24 weeks
after treatment end Subject is able to understand, consent and comply with protocol
requirements and instructions and is likely to complete the study as planned
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
Non-responders to previous treatment with pegIFN and ribavirin who failed to achieve a
sustained virologic response (SVR) for reasons other than thrombocytopenia, despite an
optimal course (dose and duration) of combination therapy with pegIFN and ribavirin
Decompensated liver disease, e.g. Child-Pugh score >6 or history of ascites or hepatic
encephalopathy or current evidence of ascites Known hypersensitivity, intolerance or
allergy to interferon (IFN), ribavirin, eltrombopag or any of their ingredients Serious
cardiac, cerebrovascular, or pulmonary disease that would preclude treatment with pegIFN
and ribavirin
Subjects with a history of any one of the following:
Suicide attempt or hospitalisation for depression in the past 5 years Any current severe or
poorly controlled psychiatric disorder
The following subjects are eligible for study participation, but must be assessed and
followed (if recommended) by a mental health professional:
- Subjects who have had a severe or poorly controlled psychiatric disorder more than 6
months ago but less than 5 years ago
- Seizure disorder that has not been well controlled History of clinically significant
bleeding from oesophageal or gastric varices Subjects with haemoglobinopathies, e.g.
sickle cell anaemia, thalassemia major Any prior history of arterial or venous
thrombosis AND two or more of the following risk factors: hereditary thrombophilic
disorders (e.g. Factor V Leiden, ATIII deficiency, etc), hormone replacement therapy,
systemic contraception (containing estrogen), smoking, diabetes, hypercholesterolemia,
medication for hypertension or cancer Pre-existing cardiac disease (New York Heart
Association (NYHA) Grade III/IV), or arrhythmias known to involve the risk of
thromboembolic events, or corrected QT interval (QTc) >450 msec Evidence of
hepatocellular carcinoma Laboratory evidence of infection with human immunodeficiency
virus (HIV) or active Hepatitis B Virus (HBV) infection Any disease condition
associated with active bleeding or requiring anticoagulation with heparin or warfarin
Therapy with any anti-neoplastic or immuno-modulatory treatment <6 months prior to the
first dose of eltrombopag.
Subjects who have had a malignancy diagnosed and/or treated within the past 5 years, except
for subjects with localised basal or squamous cell carcinoma treated by local excision or
subjects with malignancies who have been adequately treated and, in the opinion of the
oncologist, have an excellent chance of cancer-free survival Pregnant or nursing women
Males with a female partner who is pregnant History of alcohol/drug abuse or dependence
within 6 months of the study start (unless participating in a controlled rehabilitation
programme) Treatment with an investigational drug or IFN within 30 days or 5 half-lives
(whichever is longer) of the screening visit History of platelet clumping that prevents
reliable measurement of platelet counts History of major organ transplantation with an
existing functional graft Thyroid dysfunction not adequately controlled Subjects planning
to have cataract surgery Evidence of portal vein thrombosis on abdominal imaging within 3
months of the baseline visit
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
759
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Garran
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Camperdown
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Randwick
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Cairns
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Herston
Query!
Recruitment hospital [6]
0
0
GSK Investigational Site - Clayton
Query!
Recruitment hospital [7]
0
0
GSK Investigational Site - Fitzroy
Query!
Recruitment hospital [8]
0
0
GSK Investigational Site - Parkville
Query!
Recruitment hospital [9]
0
0
GSK Investigational Site - Prahran
Query!
Recruitment hospital [10]
0
0
GSK Investigational Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2606 - Garran
Query!
Recruitment postcode(s) [2]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [3]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [4]
0
0
4870 - Cairns
Query!
Recruitment postcode(s) [5]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [6]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [7]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [8]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [9]
0
0
3181 - Prahran
Query!
Recruitment postcode(s) [10]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
District of Columbia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Hawaii
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Mississippi
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Hampshire
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oklahoma
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Tennessee
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Texas
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Virginia
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Washington
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Bruxelles
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Edegem
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Gent
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Leuven
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
São Paulo
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Alberta
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
British Columbia
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Manitoba
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Ontario
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Quebec
Query!
Country [37]
0
0
Czech Republic
Query!
State/province [37]
0
0
Hradec Kralove
Query!
Country [38]
0
0
Czech Republic
Query!
State/province [38]
0
0
Olomouc
Query!
Country [39]
0
0
Czech Republic
Query!
State/province [39]
0
0
Praha 6
Query!
Country [40]
0
0
Egypt
Query!
State/province [40]
0
0
Cairo
Query!
Country [41]
0
0
Egypt
Query!
State/province [41]
0
0
Mansoura
Query!
Country [42]
0
0
Egypt
Query!
State/province [42]
0
0
Shebeen El-Kom, Menoufeya
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Besançon
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Bondy
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Dijon cedex
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Grenoble
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Lille
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Marseille Cedex 08
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Orléans
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Paris Cedex 12
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Paris Cedex 13
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Rouen
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Strasbourg
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Vandoeuvre Les Nancy
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Baden-Wuerttemberg
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Bayern
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Brandenburg
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Hessen
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Niedersachsen
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Nordrhein-Westfalen
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Rheinland-Pfalz
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Sachsen-Anhalt
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Sachsen
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Berlin
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Hamburg
Query!
Country [66]
0
0
Greece
Query!
State/province [66]
0
0
Athens
Query!
Country [67]
0
0
Greece
Query!
State/province [67]
0
0
Rio, Patras
Query!
Country [68]
0
0
Greece
Query!
State/province [68]
0
0
Thessaloniki
Query!
Country [69]
0
0
India
Query!
State/province [69]
0
0
Bangalore
Query!
Country [70]
0
0
India
Query!
State/province [70]
0
0
Chennai
Query!
Country [71]
0
0
India
Query!
State/province [71]
0
0
Hyderabad
Query!
Country [72]
0
0
India
Query!
State/province [72]
0
0
Mumbai
Query!
Country [73]
0
0
Israel
Query!
State/province [73]
0
0
Haifa
Query!
Country [74]
0
0
Israel
Query!
State/province [74]
0
0
Jerusalem
Query!
Country [75]
0
0
Israel
Query!
State/province [75]
0
0
Nazareth
Query!
Country [76]
0
0
Israel
Query!
State/province [76]
0
0
Petach Tikva
Query!
Country [77]
0
0
Israel
Query!
State/province [77]
0
0
Rehovot
Query!
Country [78]
0
0
Israel
Query!
State/province [78]
0
0
Safed
Query!
Country [79]
0
0
Israel
Query!
State/province [79]
0
0
Tel Aviv
Query!
Country [80]
0
0
Italy
Query!
State/province [80]
0
0
Calabria
Query!
Country [81]
0
0
Italy
Query!
State/province [81]
0
0
Campania
Query!
Country [82]
0
0
Italy
Query!
State/province [82]
0
0
Emilia-Romagna
Query!
Country [83]
0
0
Italy
Query!
State/province [83]
0
0
Lazio
Query!
Country [84]
0
0
Italy
Query!
State/province [84]
0
0
Liguria
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
Lombardia
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Puglia
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Sicilia
Query!
Country [88]
0
0
Korea, Republic of
Query!
State/province [88]
0
0
Busan
Query!
Country [89]
0
0
Korea, Republic of
Query!
State/province [89]
0
0
Daegu
Query!
Country [90]
0
0
Korea, Republic of
Query!
State/province [90]
0
0
Pusan
Query!
Country [91]
0
0
Korea, Republic of
Query!
State/province [91]
0
0
Seoul
Query!
Country [92]
0
0
Pakistan
Query!
State/province [92]
0
0
Lahore
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Chorzow
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Kielce
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Raciborz
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Szczecin
Query!
Country [97]
0
0
Poland
Query!
State/province [97]
0
0
Warszawa
Query!
Country [98]
0
0
Poland
Query!
State/province [98]
0
0
Wroclaw
Query!
Country [99]
0
0
Puerto Rico
Query!
State/province [99]
0
0
Ponce
Query!
Country [100]
0
0
Puerto Rico
Query!
State/province [100]
0
0
San Juan
Query!
Country [101]
0
0
Romania
Query!
State/province [101]
0
0
Bucharest
Query!
Country [102]
0
0
Romania
Query!
State/province [102]
0
0
Constanta
Query!
Country [103]
0
0
Russian Federation
Query!
State/province [103]
0
0
Moscow
Query!
Country [104]
0
0
Russian Federation
Query!
State/province [104]
0
0
Saint-Petersburg
Query!
Country [105]
0
0
Russian Federation
Query!
State/province [105]
0
0
Samara
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
St.Peterburg
Query!
Country [107]
0
0
Slovakia
Query!
State/province [107]
0
0
Bratislava
Query!
Country [108]
0
0
Slovakia
Query!
State/province [108]
0
0
Kosice
Query!
Country [109]
0
0
Slovakia
Query!
State/province [109]
0
0
Martin
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Alicante
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Barcelona
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
La Coruña
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Madrid
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Málaga
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Palma de Mallorca
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Pontevedra
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Sabadell (Barcelona)
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
San Sebastián
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Sevilla
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Valencia
Query!
Country [121]
0
0
Taiwan
Query!
State/province [121]
0
0
Changhua
Query!
Country [122]
0
0
Taiwan
Query!
State/province [122]
0
0
Chia-Yi Hsien
Query!
Country [123]
0
0
Taiwan
Query!
State/province [123]
0
0
Kaohsiung
Query!
Country [124]
0
0
Taiwan
Query!
State/province [124]
0
0
Taichung
Query!
Country [125]
0
0
Taiwan
Query!
State/province [125]
0
0
Taipei
Query!
Country [126]
0
0
Taiwan
Query!
State/province [126]
0
0
Taiyuan Hsien
Query!
Country [127]
0
0
Ukraine
Query!
State/province [127]
0
0
Donetsk
Query!
Country [128]
0
0
Ukraine
Query!
State/province [128]
0
0
Kiev
Query!
Country [129]
0
0
Ukraine
Query!
State/province [129]
0
0
Vinnitsa
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet
count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy
dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical
benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve
a Sustained Virological Response (SVR).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00529568
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00529568
Download to PDF